HNWAG
VTGN icon

High Net Worth Advisory Group’s VistaGen Therapeutics VTGN Stock Holding History

High Net Worth Advisory Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-65
Closed -$2K – 728
2022
Q2 		$2K Buy
+65
New +$2.29K ﹤0.01% 634

Other funds holding VTGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAI Capital Management
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

High Net Worth Advisory Group's VTGN Position: Q3 2022 in Review

High Net Worth Advisory Group sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 65 shares — an estimated $2K sold.

High Net Worth Advisory Group first reported a position in VTGN in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • High Net Worth Advisory Group reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 65 VistaGen Therapeutics shares in Q3 2022, an estimated $2K.
  • High Net Worth Advisory Group first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 1 quarter.
  • High Net Worth Advisory Group's VistaGen Therapeutics position peaked at $2K in Q2 2022.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on High Net Worth Advisory Group's 13F filing for Q3 2022, filed 24 Oct 2022.